Table 1.
Baseline characteristics of participants who received two doses of assigned treatment and were included in primary outcome analysis
| Vaccine (n=14 964) | Placebo (n=4902) | ||
|---|---|---|---|
| Sex | |||
| Female | 5821 (38·9%) | 1887 (38·5%) | |
| Male | 9143 (61·1%) | 3015 (61·5%) | |
| Race | |||
| White | 14 741 (98·5%) | 4830 (98·5%) | |
| Asian | 217 (1·5%) | 69 (1·4%) | |
| Other* | 6 (<0·1%) | 3 (<0·1%) | |
| Age group, years | |||
| 18–30 | 1596 (10·7%) | 521 (10·6%) | |
| 31–40 | 3848 (25·7%) | 1259 (25·7%) | |
| 41–50 | 4399 (29·4%) | 1443 (29·4%) | |
| 51–60 | 3510 (23·5%) | 1146 (23·4%) | |
| >60 | 1611 (10·8%) | 533 (10·9%) | |
| Age, years | 45·3 (12·0) | 45·3 (11·9) | |
| Bodyweight, kg | 81·3 (17·5) | 81·6 (17·7) | |
| Height, cm | 173·1 (9·1) | 173·3 (9·0) | |
| Body-mass index, kg/m2 | 26·75 (4·56) | 26·75 (4·55) | |
| Concomitant diseases (diabetes, hypertension, ischaemic heart disease, obesity)† | 3687/14 944 (24·7%) | 1235/4892 (25·2%) | |
| Risk of infection in volunteers†‡ | |||
| High | 65/14 567 (0·4%) | 23/4778 (0·5%) | |
| Medium | 3853/14 567 (26·5%) | 1280/4778 (26·8%) | |
| General | 10649/14 567 (73·1%) | 3475/4778 (72·7%) | |
Data are n (%) and mean (SD).
*
Includes Black or African American, Native Hawaiian or other Pacific Islander, or undefined.
†
Denominator shows number of participants for whom these data were available.
‡
High risk denotes those whose work involves interaction with patients with a confirmed diagnosis of COVID-19; medium risk is those who have professional contact with a large number of people, such as general practitioners, social workers, and shop assistants; and general risk denotes those with no additional risks associated with their professional activities.